Epicore Stock Option Grants

    CALGARY, Feb. 5 /CNW/ - Epicore BioNetworks Inc. announces that it has
granted stock options to directors of the company. The number of options
granted is 150,000, which is equivalent to 0.2% of Epicore's issued common
stock. Under the terms of the Epicore Stock Option Plan, which was recently
approved by shareholders at the Company's Annual General and Special Meetings
of Shareholders, options may be issued from time to time in any amount up to a
maximum of 4,702,246. The options currently being issued to directors have an
exercise price of Cdn $0.145 and expire in five years. The grant to directors
follows Company board compensation policy.

    Epicore BioNetworks Inc. is a leading producer of environmental
biotechnology and animal nutrition products. It manufactures in the USA and
markets worldwide to a variety of industries to reduce environmental pollution
and increase operational productivity. Epicore is a major supplier to the
shrimp aquaculture industry.
    Epicore BioNetworks Inc. is a public corporation with a registered office
in Calgary, Alberta, Canada and with shares listed on the Canadian Venture
Exchange (symbol EBN). (The TSX Venture Exchange has not reviewed and does not
accept responsibility for the adequacy or accuracy of this release.)

    This press release contains forward-looking statements that involve
significant risks and uncertainties. The actual results, performance or
achievements of the Company might differ materially from the results,
performance or achievements of the Company expressed or implied by such
forward-looking statements. Such forward-looking statements include, without
limitation, those regarding the development plans of the Company and the
expected timing and results of such development. We can provide no assurance
that such development will proceed as currently anticipated or that the
expected timing or results of such development will be realized. We are
subject to various risks, including the uncertainties of product development,
markets for our products and regulatory review, our need for additional
capital to fund our operations, our reliance on collaborative partners, our
history of losses, and other risks inherent in the biotechnology industry.

For further information:

For further information: Mr. William P. Long, (Chief Executive Officer),
USA, Tel: (609) 267-9118

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890